Literature DB >> 22654250

Hepatic artery dissection in a patient on bevacizumab resulting in pseudoaneurysm formation.

Daniel B Brown1.   

Abstract

Interventional radiologists are frequently encountering patients with colorectal cancer that are being treated with bevacizumab. This therapeutic agent is associated with a potentially increased risk of adverse events when invasive procedures are performed while patients are on therapy. The current case report reviews a complication related to planning angiography for radioembolization with Yttrium-90 microspheres in an individual on bevacizumab and subsequent management of the patient.

Entities:  

Keywords:  Radioembolization; bevacizumab; colorectal cancer; complications

Year:  2011        PMID： 22654250      PMCID： PMC3193328          DOI： 10.1055/s-0031-1280652

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN： 0739-9529            Impact factor:   1.513


  11 in total

1.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

2.  How many patients and how many complications does it take to decide if a drug is safe to use before surgery?

Authors:  M Margaret Kemeny
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

3.  Bevacizumab and postoperative complications after hepatic surgery for colorectal metastases.

Authors:  Nicholas J Petrelli
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

Review 4.  Pseudoaneurysm formation after catheter dissection of the common hepatic artery: report of two cases.

Authors:  J Ahn; D W Trost; H A Mitty; T A Sos
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

Review 5.  The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.

Authors:  E C Cheon; W Small; M J Strouch; S B Krantz; A Rademaker; M F Mulcahy; A B Benson; D J Bentrem; M S Talamonti
Journal:  J Surg Oncol       Date:  2010-10-01       Impact factor: 3.454

6.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Authors:  Fairooz F Kabbinavar; Joseph Schulz; Michael McCleod; Taral Patel; John T Hamm; J Randolph Hecht; Robert Mass; Brent Perrou; Betty Nelson; William F Novotny
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

7.  Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement.

Authors:  Joseph P Erinjeri; Abigail J Fong; Nancy E Kemeny; Karen T Brown; George I Getrajdman; Stephen B Solomon
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

8.  Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.

Authors:  Susan B Kesmodel; Lee M Ellis; E Lin; George J Chang; Eddie K Abdalla; Scott Kopetz; Jean-Nicolas Vauthey; Miguel A Rodriguez-Bigas; Steven A Curley; Barry W Feig
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  A review on bevacizumab and surgical wound healing: an important warning to all surgeons.

Authors:  Chad R Gordon; Yuri Rojavin; Mitul Patel; James E Zins; Generosa Grana; Brian Kann; Robert Simons; Umar Atabek
Journal:  Ann Plast Surg       Date:  2009-06       Impact factor: 1.539
View more
  4 in total

1.  Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.

Authors:  Nicholas Fidelman; Robert K Kerlan; Randall A Hawkins; Miguel Pampaloni; Andrew G Taylor; Maureen P Kohi; K Pallav Kolli; Chloe E Atreya; Emily K Bergsland; R Kate Kelley; Andrew H Ko; W Michael Korn; Katherine Van Loon; Ryan M McWhirter; Jennifer Luan; Curt Johanson; Alan P Venook
Journal:  J Gastrointest Oncol       Date:  2016-12

Review 2.  Current Approach to Planning Angiography and MAA Administration.

Authors:  Clayton W Commander; David M Mauro
Journal:  Semin Intervent Radiol       Date:  2021-10-07       Impact factor: 1.780

Review 3.  Radioembolization in the Setting of Systemic Therapies.

Authors:  Tarub S Mabud; Ryan Hickey
Journal:  Semin Intervent Radiol       Date:  2021-10-07       Impact factor: 1.780

Review 4.  Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes.

Authors:  F Edward Boas; Lisa Bodei; Constantinos T Sofocleous
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.